Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Company Overview - Protara Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing transformative therapies for cancer and rare diseases [3] - The company's lead candidate is TARA-002, an investigational cell-based therapy aimed at treating non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs) [3] - Protara is conducting an ongoing Phase 2 trial for TARA-002 in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to Bacillus Calmette-Guérin treatment, as well as a Phase 2 trial in pediatric patients with LMs [3] Upcoming Events - Management will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 3:45 pm PT in San Francisco [1] - A live webcast of the presentation will be available on the company's website, with an archive accessible for a limited time after the event [2] Additional Information - Protara is also developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who cannot meet their choline needs through oral or enteral routes [3]